

# Index

- Abdominal examination, 15
- Abdominal trauma, 203–4
- Accessory muscles, and diaphragmatic weakness, 185
- Acetaminophen, 154, 242
- Acetazolamide, 93
- Acidosis. *See* Metabolic acidosis; Respiratory acidosis
- Acinetobacter* spp., 252, 268*t*
- ACTH stimulation test, 113
- Acute lung injury (ALI)
- diagnosis of, 8
  - fibrosing alveolitis and, 282–90
  - growth factors, 290–4
  - mediators of, 11
  - quality of life for survivors of, 41
  - removal of excess fluid and protein, 276–81
  - standardized scoring systems for, 29
- Acute respiratory distress syndrome (ARDS)
- approach to clinical management of, 1–2
  - cardiovascular system and, 10–11, 12, 15, 108–20, 212–13, 211*t*, 107
  - chest radiology and diagnosis of, 16–23
  - clinical evaluation of patients, 11–16
  - definition of, 1, 6–8, 30*t*
  - epidemiology and risk factors for, 8–9, 29, 31–41, 305–9
  - history of, 8
  - idiopathic, 60
  - importance of in critical care medicine, 1
  - mediators of injury, 11
  - outcome of, 335–41
  - pathology and pathophysiology of, 9–11, 48–54, 57–8, 68–9
  - survivors of, 1, 11, 40–1, 336–41
- Adenosine triphosphate (ATP), 310
- Adrenaline
- anti-inflammatory effects of, 320
  - lactate levels and, 129, 130
  - venous return and, 113, 114–15
- Adrenocortical insufficiency, 228
- Adult respiratory distress syndrome, 8
- Advanced Trauma Life Support (ATLS), 11, 197–9
- Age, and mortality from ARDS, 39
- Airflow, and inverse ratio ventilation, 147*f*
- Airway, breathing, and circulation (ABC) approach, 14, 213
- Airway, survivors of ARDS and hyperreactivity of, 338
- Airway management
- chest tubes and, 190–1
  - endotracheal intubation and, 183–4, 186–9
  - hypoventilation and, 94*t*, 95–6
  - inhaled bronchodilators and, 191
  - mask CPAP and, 185
  - mechanical ventilation and, 184–5, 190
  - for prevention of nosocomial pneumonia, 268–9
  - total patient care and, 183–91
  - tracheostomy and, 189–90
- Airway obstruction, 94*t*, 95, 191
- Airway pressure
- hypercapnia and, 156
  - inverse-ratio ventilation and, 147*f*
  - lung compliance and, 99
  - PEEP and increase in, 90
  - respiratory mechanics and, 98, 159
  - venous return, 151
- Airway pressure-release ventilation (APRV), 148, 149*f*
- Airway resistance
- measurement of at bedside, 100
  - mechanical ventilation, 151
  - survivors of ARDS and, 337
- Albumin, 280
- Alpha-1-antitrypsin, 244
- Alpha adrenergic agents, 121, 216
- Alveolar-arterial oxygen partial pressure difference (AaDO<sub>2</sub>), 88
- Alveolar-capillary membrane, and gas transport, 81
- Alveolar ducts, 50*f*, 51*f*
- Alveolar fluid
- acute lung injury and removal of excess, 276–81
  - pathophysiology of ARDS and, 10
- Alveolar hypoventilation, 104

## 346 Index

- Alveolar macrophage, and interleukin-8, 68
- Alveolar overdistension, and mechanical ventilation, 141
- Alveolar oxygen pressure, 82
- American College of Chest Physicians, 206
- American College of Surgeons, 197
- American Thoracic Society (ATS), 8, 22, 23t, 29
- Aminoglycosides, 216, 264, 265
- Amiodarone, 58, 59f
- Ampicillin, 209t
- AMPLE history, 12
- Amrinone, 123t, 322
- Amyotrophic lateral sclerosis, 94t, 95
- Analgesics, and oxygen saturation, 152
- Anatomy, and primary survey of ARDS patient, 12
- Anemia  
as complication of ARDS, 219, 220  
multiple system organ failure and, 310–11  
oxygen delivery and, 120–1
- Anesthesia, topical, 188
- Animal models  
for gut-liver-lung connection and sepsis, 72  
for inflammation and lung injury, 74–6
- Antacids, 270
- Anteromedial pneumothoraces, 20
- Antibiotics  
nosocomial pneumonia and, 212, 263–6, 267t, 268t  
prophylactic, 271–2  
sepsis and, 208, 209t
- Antibody-coated bacteria, 259
- Anti-cytokine agents, 239–41
- Anti-endotoxin immunotherapy, 238–9
- Anti-inflammatory mediators, 66–7
- Antioxidants, 241–2, 293
- Antiproteases, 244
- Antipyretics, 152
- Anti-TNF antibodies, 240
- Anxiety, and weaning from mechanical ventilation, 167
- Aortic stenosis, 119
- APACHE II scores, 36, 39, 131
- Apoptosis, 288, 290
- ARDS. *See* Acute respiratory distress syndrome
- Arrhythmias, 190, 213
- Arterial blood gases (ABG), 86–7, 169, 339
- Arterial circulation, and systemic vascular resistance, 113
- Arterial hypoxemia, 82–7, 127–8.  
*See also* Hypoxemia
- Aspiration, of gastric contents  
clinical evaluation of ARDS patient and, 14, 15  
head injury and, 200–1  
intubation and, 188–9  
nosocomial pneumonia and, 253, 255–6, 258–9, 269  
pathology of ARDS and, 57  
as risk factor for ARDS, 36–7, 39
- Assist-control (AC) ventilation, 144, 145, 146f
- Asthma, 94t, 95, 96
- Auscultation, of chest, 12
- Auto PEEP. *See also* Intrinsic PEEP  
hypercapnia, 155  
mechanical ventilation, 145–7, 148, 151
- Aztreonam, 265, 267t
- Bacteria  
pneumonia, 36, 60, 235  
sepsis and, 206, 208
- Barbiturates, and intubation, 141
- Barotrauma  
chest radiograph and, 19  
chest tubes and, 190–1  
intrinsic PEEP and, 101, 152  
mechanical ventilation and, 145, 146–7, 148, 151, 156–8  
morbidity from ARDS, 40  
pneumoperitoneum and, 214–16  
as respiratory complication of ARDS, 210–11
- Basic fibrotic growth factor (bFGF), 291t, 294
- Benzodiazepines  
hypoventilation and, 93  
intubation and, 141  
sedation and, 194
- Beta adrenergic agents, 121, 276
- Beta-lactam antibiotics, 264, 265
- Beta<sub>2</sub>-selective agents, 191
- Bicarbonates, 126, 129, 156
- Bilateral chest tubes, 157
- Bilateral phrenic nerve injury, 94t, 95
- Biphasic positive airway pressure (BIPAP), 148, 149f
- Blind intubation, 187
- Blood plasma, and fibronectin, 284
- Blood pressure, 121–2. *See also* Hypertension; Hypotension
- Blood transfusions  
benefits of to ARDS patients, 220  
cardiovascular management and, 128–9  
multiple as risk factor for ARDS, 36, 37t, 38, 39  
oxygenation of venous blood and, 152
- Blunt chest trauma, 16
- Botulism, 94t, 95
- Bowel ileus, 213
- Brain, and multiple system organ failure, 211t
- Brain injury, 200
- Breathing, weaning trials and increased work of, 167–8
- Bronchial hyperreactivity, 338
- Bronchiolitis, 58
- Bronchiolitis obliterans and organizing pneumonia (BOOP), 60
- Bronchoalveolar lavage (BAL)  
interleukin-8 and, 68–9  
nosocomial pneumonia and, 259, 260–1
- Bronchodilators, 173, 191
- Bronchopulmonary dysplasia (BPD), 52, 54, 56f, 57f
- Bronchoscopy, 259–61, 341
- Burns, assessment of and patient care, 204–5
- Capnograph, 97
- Carbapenem, 265
- Carbohydrates, and enteral nutrition, 192
- Carbon dioxide  
alveolar-capillary membrane and elimination of, 81  
alveolar ventilation and, 92  
dead space and, 154  
gastric mucosal, 130–2  
hypoventilation and, 94t  
measures of production, 97  
pulmonary wedge pressure and elimination of, 126  
respiratory muscle pump load and, 167  
sodium bicarbonate and, 156
- Cardiac function curves, 108, 115–16
- Cardiac index, 121, 122
- Cardiac ischemia, 156
- Cardiac output  
carbon dioxide and, 93  
hypotension, 158

Cambridge University Press

978-0-521-65410-4 - Acute Respiratory Distress Syndrome: A Comprehensive Clinical Approach

Edited by James A. Russell and Keith R. Walley

Index

[More information](#)

Index 347

- maintenance of adequate in ARDS patients, 120–5
  - in survivors of ARDS, 11
  - venous return and, 113–17
- Cardiac tamponade, 201, 202
- Cardiogenic failure, 17–18
- Cardiogenic pulmonary edema, 13–14, 17–18
- Cardiogenic shock, 127
- Cardiopulmonary arrest, 184
- Cardiopulmonary bypass, 37t, 164
- Cardiovascular failure, and organ system failure scoring system (OSF), 306t
- Cardiovascular management, for ARDS patients
  - principles of, 120–9
  - tools and tests for, 129–32
- Cardiovascular system. *See also* Congestive heart failure; Coronary artery disease
  - clinical evaluation of ARDS patient, 12, 15
  - complications of ARDS and, 212–13
  - pathophysiology of ARDS and, 10–11, 108–20
  - prevention and treatment of multiple system organ failure, 211t
- Case-control studies, of ARDS, 31, 32t
- Case-fatality rates, from ARDS, 39–40
- Case series studies, of ARDS, 31, 32t
- Catecholamines
  - multiple system organ failure and, 319–22
  - venous return and, 116
- Catheters and catheterization
  - chest radiograph and venous, 18
  - pulmonary artery and, 18, 130, 223
  - suctioning catheters, 269
- Causality, and association
  - between risk factors and ARDS, 33
- C-C chemokine family, 69–70
- Cecal ligation/puncture model (CLP), 75–6
- Cefoperazone, 265
- Cefotaxime, 265, 267t, 272
- Ceftazidime, 209t, 265, 267t
- Ceftriaxone, 209t, 265, 267t
- Cefuroxime, 265
- Cell-to-cell communication, and inflammation, 72–3
- Cell death, and acute lung injury, 288, 290
- Centers for Disease Control, 256–7
- Central cyanosis, 185
- Central hypoventilation, 93
- Central nervous system. *See also* Neurologic system
  - complications of ARDS and, 218
  - dysfunction of and mortality for ARDS, 16
  - hypoventilation and, 93, 94t
- Cephalosporins, 265
- Cerebral infarction, 218–19
- Cerebral perfusion pressure, 200
- Cervical spine injury, 94t, 95, 201. *See also* Spine injury
- Chemical and drug ingestion, 58
- Chemokines, 67–71
- Chemotherapeutic toxicity, and pneumocytes, 52
- Chest radiology
  - complications of ARDS and, 19–21
  - Computerized tomography scanning of thorax, 22
  - diagnosis of ARDS, 16–17
  - differential diagnosis of ARDS, 17–18
  - endotracheal intubation and, 18, 187
  - lung contusion and, 203
  - lung injury score and, 7t
  - pneumonia and, 261
- Chest trauma
  - assessment and patient care, 201–3
  - blunt force and, 16
  - chest tubes, 191
- Chest tubes, 157–8, 190–1
- Chest wall, and hypoventilation, 94t, 95
- Chloramphenicol, 209t
- Chronic obstructive pulmonary disorder (COPD), 102, 119, 140, 168
- Cilastin, 265
- Ciprofloxacin, 209t
- Circumferential chest burns, 205
- Clinical evaluation, of patients with ARDS
  - airway management and, 183–91
  - complications of ARDS and, 210–28
  - gastrointestinal assessment and care, 191–2, 193f
  - medical history and, 13–14
  - neurologic assessment and care, 194–5, 196f
  - oxygenation and, 86–7
  - physical examination and, 14–16
  - primary survey and resuscitation, 11–13
  - secondary survey and, 13
  - sepsis syndrome and, 205–10
  - trauma assessment and care, 197–205
- Cloxacillin, 209t
- Coagulation, of blood
  - complications of ARDS and, 219–20
  - multiple system organ failure and, 211t
- Cohort study, 31
- Collagens, 285, 288
- Colloid solutions, and fluid resuscitation, 126–7
- Coma, and central nervous system, 218–19. *See also* Consciousness
- Complications, of ARDS
  - chest radiograph and, 19–21
  - laboratory assessment for, 22–23
  - therapy for, 210–28
- Complications, of endotracheal intubation, 188, 189t
- Complications, of mechanical ventilation, 156–8
- Complications, of tracheostomy, 189–90
- Computerized tomography (CT) scanning
  - abdominal trauma and, 203–4
  - of thorax, 22
- Confounding conditions or therapies, 33, 38
- Congestive heart failure, 15, 94t, 95
- Connective tissue activating protein-111, 67–8
- Consciousness, levels of, 14, 184. *See also* Coma
- Continuous lateral rotational therapy, 268
- Continuous oximetry, 86
- Continuous positive airway pressure (CPAP), 174, 185
- Continuous renal replacement therapy, 217–18
- Continuous venovenous therapy, 218
- Cooling, of patient. *See also* Temperature, body
  - carbon dioxide production and, 154

## 348 Index

- Cooling (*Continued*)  
 oxygenation of venous blood and, 152
- Coronary artery disease, 156
- Corticosteroids  
 adrenocortical insufficiency and, 228  
 immunosuppression and, 256  
 as innovative therapy in early stages of ARDS, 235–8  
 myopathy and neuromuscular blocking agents, 195, 219  
 sepsis and, 208
- Cough reflex, and intubation, 184
- Crash induction, intubation by, 186
- Critical care medicine, and ARDS, 1
- Critical illness polyneuropathy, 219
- CROP index, 171–3
- Crystalloid solutions, and fluid resuscitation, 126–7
- C-X-C chemokines, 67–9
- Cyclooxygenase inhibitors, 239
- Cyclosporin A, 75
- Cysteine, 242
- Cytokines  
 animal models of inflammation and lung injury, 74–6  
 anticytokine agents, 239–41  
 catecholamines and production of, 320  
 cell-to-cell communication during inflammation, 72–3  
 chemokines and, 67–71  
 gut-liver-lung connection and sepsis, 71–2  
 initiation and maintenance of systemic inflammation, 65–6  
 as mediators of injury in ARDS, 11, 66–7  
 multiple system organ failure, 323–4  
 PEEP and, 125  
 sepsis syndrome and, 206–8
- Dead space, of upper airways  
 carbon dioxide production and, 97  
 hypercapnia and, 154–5  
 survivors of ARDS and, 339  
 total tidal volume and, 92  
 weaning from mechanical ventilation and, 167
- Death. *See also* Mortality  
 causes of in ARDS patients, 9, 309t  
 multiple system organ failure as predictor of, 304
- multiple trauma and, 197
- Decision-making algorithms, 221
- Decubitus chest radiograph, 20–21
- Deep venous thrombosis (DVT), 221, 222, 223
- Dermatology, and complications of ARDS, 218
- Diagnosis, of ARDS. *See also* Differential diagnosis  
 chest radiology and, 16–17  
 laboratory assessment and, 22–23  
 of nosocomial pneumonia, 256–63
- Dialysis, indications for, 217
- Diaphragmatic fatigue, and weaning from mechanical ventilation, 167
- Diarrhea, and enteral nutrition, 192
- Diastolic filling, and right heart failure, 112–13
- Diastolic ventricular dysfunction, 212
- Diazepam, 188, 194
- Differential diagnosis, of ARDS  
 chest radiographs and steps in, 17–18  
 gas exchange and, 158  
 medical history of patient and, 13–14  
 pathology and, 58, 60
- Differential misclassification, 29
- Diffuse alveolar damage (DAD), 9, 48
- Diffusing capacity, 339
- Direct pulmonary insults, 16
- Discharge, medical management of ARDS survivors after, 339–41
- Disseminated intravascular coagulation (DIC), 37, 39
- Diuretics, 93
- Dobutamine, 122, 123t, 313
- Dopamine  
 hemodynamic function and, 116, 122, 123t  
 hypotension after intubation and, 189
- Dopexamine, 122, 322
- Dose-response relationship, and inhalation of nitric oxide, 154
- Drowning. *See* Near-drowning
- Drug-induced disorders, and respiratory muscle dysfunction, 166
- Drug-related adverse events, 243. *See also* Side effects
- Drugs. *See also* Antibiotics; Innovative therapy; Neuromuscular blocking agents; Vasopressors and inotropes; specific medications  
 arrhythmias and, 213  
 CNS depressants and hypoventilation, 93  
 interstitial nephritis and, 216  
 intubation and, 141, 187–8  
 oxygen saturation levels and, 152  
 rashes and, 218  
 wheezing and, 191
- Dynamic hyperinflation, 101, 164–5, 166f
- E5 (murine antibody), 238–9
- Echocardiography, 222
- Edema, and pulmonary wedge pressure, 125–6. *See also* Pulmonary edema
- Eicosanoids, 239, 242–3
- Elastase, 256
- Electrolyte abnormalities, and hypoventilation, 94t, 95
- ELR motif, 68, 69t
- Emergency management, of multiple trauma, 197–8
- Emergent intubation, 184
- Emphysema, 94t, 95
- Empiric antimicrobial therapy, 265–6
- End-diastolic pressure  
 cardiac output and, 109f, 111f, 115f  
 venous return and, 114f
- Endocrine system  
 complications of ARDS and, 228  
 respiratory muscle pump failure and disturbances of, 165–6
- Endothelium, and sepsis, 206
- Endotoxin and endotoxemia  
 animal model of gut-liver-lung connection, 72, 73  
 animal models of inflammation and lung injury, 75  
 anti-endotoxin immunotherapy, 238–9  
 lactate release and, 129  
 RANTES and, 69–70  
 splanchnic oxygen consumption and, 313–14  
 ventricular contractility and, 110, 112
- Endotracheal intubation  
 airway management and, 100, 151, 186–9  
 blind, 187

- chest radiology and, 18  
 clinical evaluation and indications for, 12–13, 14, 183, 184t  
 head injury and, 201  
 hypoventilation and obstruction of, 94t, 95, 96  
 mechanical ventilation and, 140–1  
 nosocomial pneumonia and, 255–6, 258–9
- Endotracheal suctioning, 190
- Energy, and nutritional requirements, 191–2
- Enteral nutrition, 192, 193f, 213, 269. *See also* Feeding and feeding tubes; Nutrition
- Enterobacteriaceae, 252, 268t
- Eosinophilic hyaline membranes, 51f
- Ephedrine, and hypotension, 188, 189
- Epidemiology, of ARDS. *See also* Mortality  
 case-fatality rates, 39–40  
 definition of, 8–9, 29  
 incidence and, 33–6  
 multiple system organ failure and, 305–9  
 risk factors and, 8–9, 29, 31, 33, 36–9  
 studies documenting, 29, 31–3
- Epidermal growth factor (EGF), 290–2
- Epinephrine  
 cardiac output and, 123t  
 hypotension after intubation and, 188, 189
- Erythromycin, 267t
- Escherichia coli*, 238–9
- Esophageal intubation, 18
- Esophageal pressure, 98
- Esophageal rupture, 203
- European Society of Intensive Care Medicine (ESICA), 8, 22, 23t, 29
- Euthyroid sick syndrome, 228
- Exercise, and survivors of ARDS, 338
- Exogenous IL-1ra, 240
- Expiratory positive airway pressure (EPAP), 140, 149
- Expiratory time, and mechanical ventilation, 145
- Extracorporeal carbon dioxide removal (ECCOR) and extracorporeal membrane oxygenation (ECMO), 9, 153–4
- Extremities, examination of, 15
- Exudative phase, of ARDS, 9, 48–51
- FACIT collagens (Fibril-Associated Collagens with Interrupted Triple helices), 285
- Fat embolism syndrome, 37t, 39, 197, 204, 235
- Feeding and feeding tubes. *See also* Enteral nutrition; Nutrition  
 hypercapnia and, 154  
 placement of, 18
- Fentanyl, 188, 194
- Fibrin and fibrinogen, 282–3
- Fibronectin, 283–5
- Fibrosing alveolitis, 282–90
- Fibrotic phase, of ARDS, 9, 48, 52, 54, 126
- Fick's law, 81
- FiO<sub>2</sub>. *See* Oxygenation
- Flail chest, 201, 202
- Flow triggering (flow-by), 174
- Fluid management, and cardiovascular management of ARDS, 125–7
- Fluid resuscitation, 121
- Fluoroquinolones, 265
- Forced expiratory volume in 1 second (FEV<sub>1</sub>), 337
- Forced vital capacity (FVC), 337
- Fractures, of bone  
 clinical evaluation and care of ARDS patient, 15, 204  
 of long bone, 15, 197, 204  
 pelvic, 15, 204  
 as risk factor for ARDS, 37t
- Free radicals, 241
- Fumes, inhalation of, 57–8
- Functional residual capacity (FRC), 90, 187
- Furosemide, 200
- Gag reflex, and intubation, 184
- Gamma interferon-inducible protein (IP-10), 68, 69t
- Gases, inhalation of, 57–8
- Gas exchange  
 mechanical ventilation and, 150–1, 158, 163–4, 169–70  
 survivors of ARDS and, 339
- Gastric stasis, 213
- Gastric tonometry, 130–2, 319
- Gastrointestinal system. *See also* Aspiration, of gastric contents  
 complications of ARDS and, 213–16
- infection and pH of, 270–1  
 liver-lung connection and sepsis, 71–2  
 microflora of, 254–5  
 multiple system organ failure and, 211t
- Gelatinase B, 288
- Gene therapy, and antiproteases, 244
- Gentamicin, 267t
- Germany, and incidence of ARDS, 35
- Glasgow Coma Score (GCS), 14
- Glu-Leu-Arg, 68
- Glutathione, 241–2
- Glycocalyx, 256
- Gram-negative bacteremia, 238–9
- Gram stain, 22
- Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), 224
- Growth factors, and acute lung injury, 290–4
- Guillain-Barré syndrome, 95
- Gut ischemia, 131, 132, 214
- Gut perfusion, and gastric tonometry, 131
- HA-1A (human antibody), 238–9
- Head injury, 197, 199–201, 226
- Health care system, and costs of ARDS, 1
- Heart rate, diastolic filling and right heart failure, 112–13
- Hematology  
 complications of ARDS and, 219–24  
 organ system failure scoring system (OSF) and, 306t
- Hematoma, and tracheostomy, 189–90
- Hemodynamics, and right heart failure, 112–13
- Hemoglobin, and cardiovascular management, 128–9, 220
- Hemorrhagic shock  
 multiple system organ failure and, 317  
 oxygen delivery and, 121  
 resuscitation from, 198, 199t
- Hemothorax, and chest tubes, 191, 201, 202
- Henderson-Haselbalch equation, 131
- Heparin, 221, 223–4, 225f
- Hepatocyte growth factor (HGF), 291t, 292–3

## 350 Index

- Herbicides, 58
- High-frequency ventilation (HFV), 147–8
- Host factors, and nosocomial pneumonia, 255–6
- Human immunodeficiency virus (HIV), and *pneumocystis carinii*, 36
- Hyaline membranes, 53f
- Hydrochloric acid, and aspiration of gastric contents, 57
- Hydrogen receptor blockers, 132, 213, 270
- Hypercapnia
  - hypoventilation and, 91–6
  - mechanical ventilation and, 154–6
  - permissive, 155–6, 157t
- Hyperglycemia, 225–6
- Hyperlactatemia, 129, 316–17
- Hyperleukocytosis syndrome, 224
- Hypertension. *See also* Blood pressure
  - as complication of ARDS, 212
  - endotracheal suctioning and, 190
  - intracranial, 199, 200
  - lung injury of ARDS and pulmonary, 11
- Hyperthyroidism, 228
- Hypoglycemia, 226
- Hypokalemia, 226
- Hypomagnesemia, 94t, 95, 227–8
- Hyponatremia, 226
- Hypophosphatemia, 94t, 95
- Hypotension. *See also* Blood pressure
  - causes of in ARDS, 158t
  - clinical evaluation of ARDS patients, 14, 212
  - mechanical ventilation and, 150–1, 158
  - sepsis-related syndrome and, 207t
- Hypothyroidism, 228
- Hypoventilation
  - causes of and contributors to, 94t
  - decreased alveolar oxygen pressure, 82
  - hypercapnia and, 91–6, 156
  - respiratory drive and, 104
- Hypovolemia
  - fluid resuscitation and, 127
  - hypercapnia and, 155
  - intubation and correction of, 140
  - oxygenation of venous blood, 152
- Hypoxemia. *See also* Arterial hypoxemia
  - as cause of death, 308
  - continuous oximetry and, 86
  - intrapulmonary shunting and, 10
  - mechanical ventilation and, 152–4, 163–4
- Hypoxia
  - intubation and, 188
  - multiple system organ failure and, 310–11, 312, 314, 315–17, 318f
  - oxygen delivery and, 120
- Idiopathic ARDS, 60
- Idiopathic interstitial fibrosis, 60
- Idiopathic pulmonary fibrosis (IPF), 285
- IgM antibodies, 238–9
- Imipenem, 209t, 265
- Immune system. *See also* Inflammatory response
  - enteral nutrition and, 192, 269
  - host factors in nosocomial pneumonia, 255–6
- Impaired tissue oxygen extraction, 313
- Inception cohort, 30–1
- Incidence, of ARDS, 33–6
- Incidence density, 33
- Increased intracranial pressure (ICP), 199, 200
- Infant respiratory distress syndrome (IRDS), 233, 234
- Infections. *See also* Inflammatory response; Pneumonia
  - computerized tomography scans of chest and, 22
  - pathology of ARDS and, 54
  - surveillance and control of, 269–70, 271t
  - of wounds, 210
- Inflammatory response. *See also* Immune system
  - animal models of lung injury and, 74–6
  - cell-to-cell communication during, 72–3
  - chemokines and, 67–71
  - clinical evaluation of ARDS patient and, 14
  - cytokines and, 65–6
  - gut-liver-lung connection and sepsis, 71–2
  - multiple system organ failure and catecholamines, 319–22
  - pro- and anti-inflammatory mediators, 66–7
- Inhalation. *See also* Smoke inhalation
  - of nitric oxide, 234
  - of noxious fumes and gases, 57–8
- Innovative therapy, for ARDS. *See also* Drugs
  - anticytokine agents, 239–41
  - anti-endotoxin immunotherapy, 238–9
  - antioxidants, 241–2
  - antiproteases, 244
  - corticosteroids and early stages of, 235–8
  - cyclooxygenase inhibitors, 239
  - eicosanoids, 242–3
  - nitric oxide, 234–5
  - pentoxifylline, 243–4
  - platelet-activating factor antagonists, 242
  - surfactant replacement, 233–4
- Inotropes, and cardiac output, 121–2, 123t
- Inspiratory positive airway pressure (IPAP), and mechanical ventilation, 140, 149
- Inspiratory time, and mechanical ventilation, 145
- Insulin, infusion protocol for, 227f
- Insulin-like growth factor (IGF), 290
- Integrative indices, and weaning from mechanical ventilation, 171–3
- Interleukin-1 (IL-1)
  - acute lung injury and, 291t, 294
  - anticytokine agents and, 240
  - initiation and maintenance of inflammatory response, 65–6, 70–1, 74
  - sepsis syndrome and, 206, 208
- Interleukin-1 receptor antagonist, 66
- Interleukin-6, 112, 320
- Interleukin-8 (IL-8), 68–9, 71t, 73
- Interleukin-10 (IL-10)
  - acute lung injury and, 66
  - endotoxin-induced inflammation and, 75–6
  - multiple system organ failure and, 320, 321f
- Intermittent hemodialysis, 217
- Intermittent mandatory ventilation (IMV), 144, 174–5, 177–9
- Intracranial hypertension, management of, 199, 200
- Intracranial pressure, and hypercapnia, 156

- Intrinsic PEEP, 101–2, 103*f*. *See also* Auto PEEP
- Inverse-ratio ventilation (IRV), 144–7, 151
- Investigational modes, of mechanical ventilation, 147–8
- Ipratropium, 191
- Keratinocyte growth factor (KGF), 291*t*, 293
- Ketamine, 188
- Ketoconazole, 243
- Kidneys. *See also* Renal failure complications of ARDS and, 216–18 lactate clearance, 129 prevention and treatment of multiple system organ failure, 211*t*
- Kreb's cycle, 129
- Kupffer cells, 72, 73, 74
- Kyphoscoliosis, 94*t*, 95
- Laboratory assessment, and diagnosis of ARDS, 22–23
- Lactate cardiovascular management and, 129–30 multiple system organ failure and, 315–17, 318*f*
- Lactic acidosis, 130
- Laparotomy, 204
- Laryngoscopy, 186–7, 188
- Latency-associated peptide (LAP), 292
- Left ventricular pressure-volume relationships, 110*f*
- Legionella* spp., 268*t*
- Legionnaire's disease, 60
- Leukemia, 224
- Leukocytes chemokines and, 67 IL-1 and TNF-dependent cytokine networks, 65–6 as mediators of acute lung injury, 11 multiple system organ failure and, 322 ventricular contractility and, 112
- Leukotriene B<sub>4</sub>, 281
- Lidocaine, 188
- Limited absorption, of enteral nutrition, 192
- Lipids, and enteral nutrition, 192
- Lipopolysaccharide (LPS), 72, 74, 206
- Liposomal PGE, 243
- Liver disease of and mortality from ARDS, 39 gut-lung connection and sepsis, 71–2 multiple system organ failure and, 211*t*
- Long bone fractures, 15, 197, 204
- Lorazepam, 194
- Lower inflection point (LIP), 142–4
- Lung, and ARDS. *See also* Acute lung injury fibrotic phase of, 52, 54 gut-liver connection and sepsis, 71–2 hypoventilation and, 94*t*, 96 measures of function and blood oxygenation, 88–9 oxygen transport and, 80–1 proliferative phase of, 51–2 pulmonary pathophysiology and, 80–105 pulmonary wedge pressure and edema, 125–6 surgical or postmortem findings, 48–51
- Lung compliance decrease in and early ARDS, 10 measurement of at bedside, 98–100
- Lung injury animal models for inflammation and, 74–6 contusion of, 37*t*, 202–3 inverse ratio ventilation and, 147 scoring systems for, 7–8 tidal volume and, 142
- Lung protection strategy, 143–4
- Lung volume inverse ratio ventilation and, 147*f* survivors of ARDS and, 338
- Macrophages. *See* Resident macrophages
- Magnesium deficiency, 227–8
- Mallory's hyaline, 52
- Malnutrition. *See also* Nutrition hypoventilation and, 94*t*, 95 nosocomial pneumonia and, 269 respiratory muscle dysfunction and, 165–6
- Mannitol, 200
- Mask CPAP, 185
- Massive hemothorax, 201, 202
- Matrix degradation, and pulmonary fibrosis, 288
- Maximum compartmental amplitude to VT ratio (MCA/VT), 171
- Maximum inspiratory pressure (MIP), 104, 170
- Mechanical ventilation barotrauma and, 145, 146–7, 148, 151, 156–8 choice of mode, 144–8 complications of, 156–8 goals of, 141 hypercapnia and, 154–6 hypoventilation and, 82 hypoxemia and, 152–4 initial ventilator settings, 145*t*, 149 initiation of, 139–41 nosocomial pneumonia and, 255, 268–9 oxygen demand and changes in, 119 PEEP levels and, 142–4 principles of, 141*t* primary survey and indications for, 12–13, 140*t* renal failure and, 216 stabilizing of patient, 150–1 tidal volume and, 139, 141–2 transpulmonary pressure and, 98 weaning of patient from, 163–79
- Mediastinitis, 203
- Medical history, of ARDS patient, 13–14, 340
- Meropenem, 265
- Mesenchymal cellular changes, and acute lung injury, 288–90
- Metabolic acidosis, 93
- Metabolic alkalosis, 93, 129
- Metabolism acidosis and alkalosis, 93, 129 complications of ARDS and, 225–8 respiratory muscle pump failure, 154
- Methacholine, 338
- Methemoglobin, and inhaled nitric oxide, 154
- Methicillin-resistant *Staphylococcus aureus* (MRSA), 265–6, 268*t*
- Methylprednisolone, 236*f*, 237*f*
- Metronidazole, 209*t*
- Metalloproteinases, 288
- Microbial colonization, and nosocomial pneumonia, 253–5
- Microbiology, of nosocomial pneumonia, 252

## 352 Index

- Midazolam, 188, 194  
 Minute ventilation, 96–7, 170  
 Misclassification, and definition of ARDS, 29  
 Mixed venous oxygen desaturation, 84, 85f, 127–8  
 “Modified sniffing” position, 186  
 Monobactam, 265  
 Monokine induced by gamma interferon (MIG), 68, 69t  
 Morbidity, from ARDS, 40–1, 129. *See also* Survival and survivors  
 Morphine, 194  
 Mortality, from ARDS. *See also* Death  
 alveolar fluid clearance and, 278–9  
 barotrauma and, 157  
 central nervous system dysfunction and, 16  
 complications of ARDS and, 63  
 gastric mucosal acidosis and, 319  
 hyperlactatemia and, 129  
 multiple system organ failure and, 305, 308, 316–17  
 new therapeutic approaches and, 233  
 pneumonia and, 212, 251  
 pulmonary angiography and, 222–3  
 rates of, 1, 28, 39–40, 335  
 sepsis syndrome and, 205  
 supranormal oxygen delivery and, 122  
 Mucociliary clearance and mucosal defenses, and infection, 256, 257t  
 Multiple inert gas elimination technique (MIGET), 153  
 Multiple sclerosis, 94t, 95  
 Multiple system organ failure (MSOF), and ARDS  
 alternative mechanisms of, 322–4  
 catecholamines and inflammation, 319–22  
 definitions of, 304–5  
 epidemiology of, 305–9  
 mortality from, 40, 305, 308, 316–17  
 pathophysiology of, 310–19  
 prevention of, 211t  
 scoring systems for, 23, 305t, 306t, 307t  
 sepsis and, 11, 207t  
 Multiple trauma, and ARDS, 197–9, 201  
 Muscle relaxants, 195  
 Muscular dystrophy, 94t, 95  
 Myasthenia gravis, 94t, 95  
 Myeloperoxidase (MPO) assay, 75  
 Myopathy  
 as complication of ARDS, 219  
 hypoventilation and, 94t, 95  
 steroid-induced, 195  
 N-acetylcysteine (NAC), 242  
 Narcotics  
 hypoventilation and, 93  
 intubation and, 141  
 for pain control, 194  
 Nasogastric (NG) tubes, 18, 186  
 National Institute of Health, Heart and Lung Task Force on Respiratory Diseases, 33, 36  
 Near-drowning, and ARDS, 37t, 57  
 Nephrotoxins, 216  
 Neurogenic pulmonary edema, 15, 199–200  
 Neurologic failure, and organ system failure scoring system (OSF), 306t  
 Neurologic system. *See also* Central nervous system; Peripheral nervous system  
 clinical evaluation and patient care, 15–16, 194–5, 196f  
 complications of ARDS and, 218–19  
 Neuromuscular blocking agents  
 intubation and, 188  
 myopathy and prolonged weakness secondary to use of, 219  
 neurologic assessment and patient care, 194–5, 196t  
 Neuromuscular transmission  
 hypoventilation and, 94t, 95  
 neuromuscular blocking agents, 188, 194–5, 196t, 219  
 weaning from mechanical ventilation, 164–7  
 Neutrophil activating protein-2, 67–8  
 Neutrophils  
 acute lung injury and activation or adherence of, 11  
 multiple system organ failure, 323  
 neutrophil activating protein-2, 67–8  
 pathology of ARDS, 68–9  
 sepsis syndrome and, 207  
 NG tube. *See* Nasogastric tube  
 Nitric oxide  
 gas exchange and mechanical ventilation, 153–4  
 innovative therapy and, 234–5  
 myocardial contractility and, 112  
 Nitroprusside, 313  
 Nocodazole, 280  
 Nomogram-based dosing, of heparin, 224, 225f  
 Noninflammatory cells, and chemokines, 70–1  
 Noninvasive leg studies, 222  
 Noninvasive positive pressure ventilation (NIPPV), 140  
 Norepinephrine, 122, 123t, 320  
 Nosocomial pneumonia, and ARDS. *See also* Pneumonia  
 antimicrobial therapy for, 263–6  
 as complication of ARDS, 190, 210, 211–12  
 diagnosis of, 256–63  
 incidence of, 251  
 microbiology of, 252  
 pathogenesis of, 252–6  
 prevention of, 266–72  
 sepsis and, 305  
 Nutrition. *See also* Enteral nutrition; Feeding and feeding tubes; Malnutrition  
 hypoxemia and, 154  
 nosocomial pneumonia and, 269  
 patient care and, 191–2  
 Obesity, and hypoventilation, 94t, 95  
 Obstetrics, and hyponatremia, 226  
 Obstructive sleep apnea, 119  
 Odds ratio, for individual risk factors, 38  
 Ohm’s law, 99, 100  
 Open lung biopsy, 224  
 Open pneumothorax, 201  
 Organ failure scoring, 306t, 308–9  
 Oropharynx  
 microflora of, 254  
 suctioning of, 190  
 Orotracheal intubation, 186–7, 188  
 Outcome, of ARDS. *See also* Survival and survivors  
 medical management after discharge, 339–41  
 mortality and, 335  
 pulmonary function test abnormalities and, 337–9  
 roentgenographic changes and, 337  
 symptoms and limitations in survivors, 336–7  
 Oxothiazolidine carboxylate (OTC), 242



- Oxygenation  
 hypoventilation, 82  
 intubation and, 140, 184t  
 mechanical ventilation, 150  
 pulmonary pathophysiology and increase of, 87–8
- Oxygen consumption  
 carbon dioxide production and, 97  
 hypoxemia and, 152  
 oxygen delivery and, 117–20, 314  
 tissue hypoxia and increased demand, 313–14  
 weaning from mechanical ventilation and, 167–8, 169t
- Oxygen delivery  
 cardiac output and, 120–1  
 extraction ratio and mixed venous oxygen desaturation, 85f  
 hypoxemia and, 152  
 multiple system organ failure and, 314–15  
 oxygen consumption and, 117–20, 314  
 supranormal, 122, 124  
 in survivors of ARDS, 11  
 tissue hypoxia and, 310–11
- Oxygen pressure  
 definition of ARDS, 8, 22, 23t  
 lung injury score and, 7t  
 measures of lung function and, 88–9
- Oxygen saturation  
 arterial hypoxemia and, 127–8  
 measurement of, 87  
 target level of in ARDS patients, 89–90
- Oxygen toxicity, and morbidity from ARDS, 40
- Oxygen transport  
 clinical assessment of, 86–7  
 gas transport across alveolar-capillary membrane, 81  
 measures of lung function and, 88–9  
 review of mechanism of, 80–1
- Pain control, 194–5, 196f
- Pancreatitis, 37t, 214
- PaO<sub>2</sub>/FiO<sub>2</sub>. *See* Oxygenation; Oxygen pressure
- Paradoxical respiratory movement, 185
- Paralysis, drug-induced, 195. *See also* Therapeutic paralysis
- Paraquat, 58, 59f
- Pathology, of ARDS, 9  
 chemical and drug ingestion, 58  
 classic features of, 48–54  
 differential diagnosis and, 58, 60  
 gas and fume inhalation, 57–8  
 infections and, 54  
 liquid aspiration and, 57  
 neutrophils and, 68–9
- Patient, total care for ARDS. *See also* Clinical evaluation; Innovative therapy; Outcome; Positioning, of patient; Survival and survivors  
 airway management for, 183–91  
 complications of ARDS and, 210–28  
 gastrointestinal assessment and care of, 191–2, 193f  
 neurologic assessment and care of, 194–5, 196f  
 sepsis syndrome and, 205–10  
 trauma assessment and care of, 197–205
- Patient history, 13–14, 340
- PEEP. *See* Positive end-expiratory pressure
- Pelvic fractures, 15, 204
- Penicillin, 265
- Pentothal, 189
- Pentoxifylline, 243–4, 321, 322
- Perfusion distribution, and multiple system organ failure, 311–13
- Peripheral nervous system, and complications of ARDS, 219. *See also* Neurologic system
- Peritoneal lavage, 203, 204
- Permissive hypercapnia, 155–6, 157t
- Petechial rashes, 218
- pH  
 of aspirated liquids, 57  
 of gastrointestinal system and infection, 270–1  
 gastric tonometry and, 131–2, 319  
 hypoventilation and, 93  
 microflora of stomach and, 254
- Phagocytic cell function, and infection, 256, 257t
- Phenylephrine, 122, 123t
- Phosphodiesterase inhibitors, 122, 320–2
- Phrenic nerve injury, 164
- Physical examination, 14–16, 341
- Piperacillin, 209t, 265, 267t
- Plasminogen-activator inhibitor type 1 (PAI-1), 282–3
- Platelet-activating factor antagonists, 242
- Platelet-derived growth factor (PDGF), 285, 290, 291t
- Platelet factor-4, 68, 69t
- Pleural effusions, and computerized tomography scans, 22
- Pleural pressure, and lung compliance, 100
- Pneumocystis carinii* pneumonia, 36, 235
- Pneumomediastinum, 21
- Pneumonia, and ARDS. *See also* Nosocomial pneumonia  
 aspiration of gastric contents and, 201  
 bacterial, 36, 60, 235  
 chest radiographs and diagnosis of, 17  
 incidence of, 251  
 pathology of ARDS and, 60  
 as risk factor for ARDS, 37, 39  
 sepsis and, 206, 208  
 in survivors of ARDS, 340  
 V/Q mismatch and lobar, 83
- Pneumopericardium, 21
- Pneumoperitoneum, 214–16
- Pneumothorax  
 chest radiograph and, 18, 19–21, 22  
 chest tubes and, 190–1  
 esophageal rupture and, 203  
 mechanical ventilation and, 156–8  
 as respiratory complication of ARDS, 210–11
- Polymicrobial infections, 252
- Polymorphonuclear leukocytes (PMNs), 323
- Polymyositis, 94t, 95
- Polymyxin B, 271
- Polyneuropathy, 219
- Positioning, of patient  
 endotracheal intubation and, 186  
 hypoxemia and mechanical ventilation, 152–3  
 prevention of nosocomial pneumonia and, 267–8  
 weaning from mechanical ventilation and, 173–4
- Positive end-expiratory pressure (PEEP)  
 auto PEEP, 145–7, 148, 151, 155  
 cardiac output and, 124–5  
 chest tubes and, 157  
 hypercapnia and, 155  
 hypoxemia and, 152  
 intrinsic, 101–2, 103f  
 lung compliance and, 99

## 354 Index

- Positive end-expiratory pressure  
(Continued)  
mechanical ventilation and,  
141, 142–4, 150  
multiple system organ failure  
and, 312  
pathophysiology of ARDS and,  
11  
pulmonary pathophysiology  
and, 90  
studies assessing ARDS ther-  
apy and development of, 64  
Preoxygenation, and intubation,  
140, 187  
Pressure-control ventilation  
(PCV), 144–5, 146f  
Pressure-cycled modes, of  
mechanical ventilation, 144  
Pressure support ventilation  
(PSV), 144, 175–9  
Pressure-volume relationships  
measurement of, 98, 101  
mechanical ventilation and,  
142, 143f  
Prevalence, of ARDS, 33  
Prevention  
of ARDS, 28  
of hyponatremia, 226  
of multiple system organ failure  
in ARDS, 211t  
of nosocomial pneumonia,  
266–72  
Primary survey, of patient with  
ARDS, 11–13  
Prognostic factors, and definition  
of ARDS, 31  
Pro-inflammatory mediators,  
66–7, 72  
Proliferative phase, of ARDS, 9,  
48, 51–2, 126  
Promotional-assist ventilation  
(PAV), 148  
Prone position, and hypoxemia,  
152–3  
Prophylactic antimicrobials, 271–2  
Propofol, 141, 188  
Prospective cohort study, 32t  
Prostacyclin (PG-I), 239, 243, 314  
Prostaglandin E (PGE), 239,  
242–3, 314  
Protected BAL (PBAL), 259, 261  
Protected specimen brushing  
(PSB), 259, 260  
Protein  
alveolar fluid clearance and,  
278t, 280–1  
nutritional requirements for,  
191, 192  
Proteolytic enzymes, 244  
*Pseudomonas aeruginosa*, 208, 252,  
264, 265, 268t, 281  
Psychological problems, and  
weaning from mechanical  
ventilation, 168  
Pulmonary angiography, 222–3  
Pulmonary artery catheter, 18, 30  
Pulmonary contusion, 37t  
Pulmonary edema  
alveolar edema, 278t  
crystalloid solution and, 127  
neurogenic, 15, 199–200  
pathophysiology of ARDS, 10  
pulmonary wedge pressure,  
125–6  
Pulmonary embolus, 17  
Pulmonary epithelial cells, and  
lung-derived RANTES, 70  
Pulmonary fibrosis, 282, 285  
Pulmonary function, in survivors  
of ARDS, 40–1, 337–9, 341  
Pulmonary infarction, 17  
Pulmonary pathophysiology, in  
ARDS. *See also* Pulmonary  
edema  
airway resistance and, 100  
arterial hypoxemia and, 82–7  
clinical assessment of oxygena-  
tion, 86–7  
direct insults and, 16  
gas transport across alveolar-  
capillary membrane, 81  
hypercapnia and hypoventila-  
tion, 91–6  
lung compliance and, 98–100  
oxygenation and oxygen satu-  
ration, 87–90  
oxygen consumption and car-  
bon dioxide production, 97  
PEEP and, 90, 101–2  
pressure-volume relationships  
and, 101  
respiratory drive and, 104–5  
respiratory mechanics and,  
97–8  
respiratory muscle strength  
and, 103–4  
ventilation measures and, 96–7  
Pulmonary thromboembolism  
(PTE), 221–2, 223–4  
Pulmonary veins, and arterial  
hypoxemia, 83  
Pulmonary wedge pressure, and  
edema formation, 125–6  
Pulse oximetry saturation, 150  
Pulse and reflectance oximetry, 86  
Pulsus paradoxus, and hypoventi-  
lation, 96  
Purpura, 218  
Pyruvate dehydrogenase (PDH),  
129  
Quality of life, for survivors of  
ARDS, 1, 41  
Radiographic dye, and renal fail-  
ure, 216  
Ramsay Scale of Sedation, 195t  
Randomized control studies, of  
ARDS, 31, 32t  
Random misclassification, 29  
RANTES (C-C supergene fam-  
ily), 69–70  
Rapid shallow breathing, 170–1,  
172f  
Rashes, and drug reactions, 218  
Reactive airways disease, 94t, 96  
Reactive oxygen metabolites  
(ROMs), 322–3  
Recombinant IL-1ra, 240  
Red blood cells, 128–9, 220  
Refractory respiratory failure, 308  
Refractory septic shock, 207t  
Relative risk, of ARDS, 38  
Renal failure. *See also* Kidneys  
hemoglobin concentrations  
and, 128  
mechanical ventilation and, 216  
organ system failure scoring  
system (OSF) for, 306t  
Reperfusion injury, 322–3  
Resident macrophages, 70–1, 72–3  
Resistance to venous return,  
113–14  
Respiratory acidosis  
hypoventilation and, 93, 94t, 95  
intubation and, 184–5  
mechanical ventilation and,  
155–6, 158, 160t  
respiratory muscle dysfunction  
and, 165  
Respiratory alkalosis, 129  
Respiratory arrest, 12  
Respiratory burst, 241  
Respiratory center output, 164  
Respiratory compliance, 7t  
Respiratory drive, 104–5  
Respiratory exam, 15  
Respiratory failure  
mortality from ARDS and, 39,  
308  
organ system failure scoring  
system (OSF) for, 306t  
Respiratory muscles  
fatigue of, 166–7  
hypoventilation and, 94t, 95  
pulmonary pathophysiology  
and strength of, 103–4

- weaning from mechanical ventilation and, 164–8
- Respiratory rate, and measures of ventilation, 96–7
- Respiratory system complications of ARDS and, 210–2
- host factors in nosocomial pneumonia, 256, 257t
- mechanics of and mechanical ventilation, 159–60
- mechanics of and pathophysiology of ARDS, 97–8
- support other than ventilation, 190–1
- survivors of ARDS and, 336, 340
- Resuscitation fluid, 121
- multiple trauma and, 198
- of patient with ARDS, 11–13
- Retrospective case reports, 31, 32t
- Rib cage-abdominal motion, 171
- Right heart failure, and hemodynamics, 112–13
- Right mainstem intubation, 188
- Right ventricular end-diastolic pressure (RVEDP), 223
- Ringer's lactate, 126–7
- Risk factors, for ARDS causality and, 33
- definition of, 8–9, 31
- epidemiology and, 36–9
- misclassification of ARDS and, 29
- Salbutamol, 191
- San Francisco, and incidence of ARDS, 35–6
- Sedation mechanical ventilation and, 147, 148, 149, 150, 154
- oxygen demand and, 119, 313
- patient care and, 194–5, 196f
- Selective decontamination of digestive tract (SDD), 271–2
- Sepsis. *See also* Septic shock
- antibiotic regimens for, 209t
- assessment of and patient care, 205–10
- biologics targeting IL-1 and TNF, 66
- cardiac function curve and venous return, 116
- diagnosis of ARDS and, 22
- gut-liver-lung connection and evolution of, 71–2
- hypoventilation and, 94t, 95
- impaired tissue oxygen extraction and, 313
- lactic acidosis and, 129, 130
- mortality from ARDS and, 8, 39, 40
- multiple system organ failure and, 11, 305
- polymicrobial-induced, 75–6
- as risk factor for ARDS, 36, 37t, 39
- ventricular pressure-volume relationships, 109–12
- Septic shock, 14, 207, 209t, 235, 317
- Serum lipofuscin, 323
- Shock clinical evaluation of ARDS patients, 14
- esophageal rupture and, 203
- hemorrhagic, 121, 198, 199t, 317
- hypoventilation and, 94t, 95
- intubation and, 184t
- mixed venous oxygen desaturation and, 84
- oxygen delivery and, 124
- pulmonary thromboembolism and, 221, 223
- renal failure and, 216
- as risk factor for ARDS, 37t, 38
- septic, 14, 207, 209t, 235, 317
- splanchnic circulation and, 311, 312
- Shunts and shunting, 83, 87–8
- Sickle-cell disease, 86
- Sickness Impact Profile (SIP), 40, 336–7
- Side effects, of medications, 235, 243
- Sinusitis, 269
- Skeletal muscle atrophy, 166
- Sleep apnea, 119
- Smoke inhalation, and ARDS, 37t, 58, 204–5
- Smoking, of tobacco, 336, 340
- Society of Critical Care Medicine, 206
- Sodium bicarbonate, 156
- Sodium transport, and alveolar fluid clearance, 276, 277f
- Soluble TNF receptors, 240
- Spine injury, 199, 201. *See also* Cervical spine injury
- Spirometry, 337
- Splanchnic circulation, and endotoxemic shock, 311, 312
- Spontaneous breathing, trials of, 174, 177–9
- Squamous metaplasia, 54f
- Staphylococcus aureus*, 208, 252, 254, 265–6, 268t
- Stenotrophomonas maltophilia*, 252
- Steroid muscle relaxants, 195
- Steroid myopathy, 94t, 95, 195
- Stevens-Johnson syndrome, 218
- Storage lesions, of red blood cells, 220
- Streptococcus pneumoniae*, 268t
- Streptokinase, 223
- Stress gastritis, 192
- Succinylcholine, 141, 195
- Sucralfate, 270
- Suctioning catheters, 269
- Surfactant replacement, 233–4
- Supergene families, of chemotactic peptides, 67
- Superoxide dismutase (SOD), 241
- Supranormal oxygen delivery, 122, 124
- Surgical pulmonary embolectomy, 223
- Surveillance, and infection control, 269–70, 271t
- Survival and survivors, of ARDS medical management after discharge, 339–41
- pathophysiology and, 11
- pulmonary function testing and, 337–9, 341
- quality of life for, 1, 40–1
- roentgenographic changes in, 337
- symptoms and limitations in, 336–7
- Systemic inflammatory response syndrome (SIRS), 206, 207t
- Systemic vascular resistance (SVR), 113, 158
- Systolic dysfunction, 212
- Tachycardia, and mechanical ventilation, 150–1
- Tazobactam, 267t
- Temperature, body. *See also* Cooling hypercapnia and, 154
- oxygenation of venous blood and, 152
- oxygen demand and, 119
- Tension pneumothorax, 201, 210–11
- Tetanus, 94t, 95
- Therapeutic paralysis, and mechanical ventilation, 147, 148, 149, 152, 154, 314
- Thoracotomy, 198–9
- Thrombocytopenia, 219
- Thrombolytic therapy, 223
- Thromboxane, 239, 243
- Thyroid hormones, 228

Cambridge University Press

978-0-521-65410-4 - Acute Respiratory Distress Syndrome: A Comprehensive Clinical Approach

Edited by James A. Russell and Keith R. Walley

Index

[More information](#)356 *Index*

- Thyroxine, 228
- Tidal breathing, and mechanical ventilation, 139
- Tidal volumes  
dead space and, 92  
lung compliance and, 99  
mechanical ventilation and, 96–7, 141–2, 149, 151  
respiratory mechanics and, 98, 104  
rib cage ratio (RCVT) and, 171
- Tissue plasminogen activator, 283
- Total lung capacity (TLC), and transpulmonary pressure, 91*f*
- Total parenteral nutrition (TPN), 192
- Tracheal gas insufflation (TGI), 148
- Tracheal injury, and intubation, 18
- Tracheostomy, 189–90
- Trial of transfusion in critical care (TRICC), 220
- Transforming growth factor- $\alpha$  (TGF- $\alpha$ ), 278, 290–2
- Transforming growth factor- $\beta$  (TGF- $\beta$ ), 291*t*, 292
- Transmission oximeters, 86
- Transportation, of patient and intubation, 184
- Transpulmonary pressure, 91*f*, 97–8
- Trauma. *See also* Barotrauma;  
Fractures; Volutrauma  
assessment of and patient care, 197–205  
of chest, 16, 191, 201–3  
as risk factor for ARDS, 36, 37–8, 39
- Traumatic air embolism, 201, 202
- Tumor necrosis factor- $\alpha$  (TNF)  
acute lung injury and, 291*t*, 293–4  
anticytokine agents and, 240  
initiation and maintenance of inflammatory response, 65–6, 70–1, 74, 75–6  
multiple system organ failure, 320, 321*f*  
sepsis syndrome and, 206–8  
splanchnic blood flow and, 314  
systolic contractility and, 112
- Ulcers, of gastrointestinal system, 192, 213–14, 215*f*
- United Kingdom, and incidence of ARDS, 35
- University of Washington, 8
- Upper abdominal surgery, 164
- Upper airway burn injury, 204
- Upper airways obstruction, 94*t*, 95
- Upper gastrointestinal hemorrhage, 213
- Upper inflection point (UIP), 98, 142
- Urokinase, 282–3
- Utah, and incidence of ARDS, 35
- Vancomycin, 209*t*, 266
- Vascular endothelial growth factor (VEGF), 291*t*, 294
- Vascular injury, and sepsis, 207
- Vascular permeability, and pathophysiology of ARDS, 9–10
- Vasoactive drugs, 152, 313, 322
- Vasopressin, 123*t*
- Vasopressors, 121–2, 123*t*, 189
- Vecuronium, 195
- Venous catheter, and chest radiograph, 18
- Venous return  
cardiac output and, 113–17  
mechanical ventilation and, 150–1
- Ventilation. *See also* Hyperventilation; Hypoventilation; Mechanical ventilation  
cardiac output and, 124  
intubation and, 184*t*  
measures of, 96–7  
Ventilation-perfusion lung scan, 222  
Ventilator-induced lung injury, 40  
Ventilatory circuit changes, and nosocomial pneumonia, 269  
Ventricular preload, in survivors of ARDS, 11  
Ventricular pressure-volume relationships, 108–12  
Viral pneumonia, 340  
Vital capacity, and maximum inspiratory pressure, 104  
Vitamin K, 219, 220  
Volume-controlled IRV (VC-IRV), 144–5  
Volume-cycled modes, of mechanical ventilation, 144  
Volutrauma, 151  
V/Q mismatch  
hypoxemia and, 83, 87  
measurement of carbon dioxide production, 97
- Weakness, muscular, 185, 195, 219. *See also* Myopathy
- Weaning, from mechanical ventilation  
methods of, 173–9  
predicting outcome of, 168–73  
pulmonary gas exchange and, 163–4
- West's zone 1 lung, and pulmonary wedge pressure, 126
- Wheezing, 191
- Whole body oxygen uptake, 118–19
- Wound infections, 210
- Xanthine oxidase, 322, 323